419 Davis Drive
Suite 100
Morrisville, NC 27560
United States
919 328 4400
https://www.liquidia.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 145
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. Roger A. Jeffs Ph.D. | CEO & Director | 532.23k | N/A | 1962 |
Mr. Michael Kaseta | COO & CFO | 627.85k | N/A | 1977 |
Mr. Russell Schundler | General Counsel & Corporate Secretary | 541.92k | N/A | 1975 |
Mr. William R. Kenan Jr. | Co-Founder | N/A | N/A | N/A |
Dr. Ginger Denison | Co-Founder | N/A | N/A | N/A |
Jennifer Almond | Director of Investor Relations & Corporate Communications | N/A | N/A | N/A |
Ms. Sarah Krepp SPHR | Vice President of People & Culture | N/A | N/A | N/A |
Mr. Jason Adair | Chief Business Officer | N/A | N/A | 1974 |
Dr. Tushar Shah M.D. | Senior Vice President of Product Development | 792.36k | N/A | 1961 |
Mr. Scott Moomaw | Chief Commercial Officer | N/A | N/A | 1971 |
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Liquidia Corporation’s ISS Governance QualityScore as of March 1, 2024 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder Rights: 6; Compensation: 10.